Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
Azizi
M
M
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D002216:Captopril / Q000493:pharmacokinetics*; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D019808:Losartan / Q000493:pharmacokinetics*; D012084:Renin-Angiotensin System / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D065168:Bradykinin Receptor Antagonists; C065679:icatibant; D002216:Captopril; D019808:Losartan; D001920:Bradykinin